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Abstract
Purpose Human epidermal growth factor receptor 2 (Erbb2/
HER2) overexpression, which was previously detected in inva-
sive breast cancer, has now been implicated in advanced gastric
cancer (GC) and gastroesophageal junction cancer (GEC). A
study was conducted to determine the rate of HER2 positivity
in patients with locally advanced or metastatic GC and GEC in
Malaysia and to assess the impact of various demographic and
clinical parameters on HER2 positivity.
Methods A total of 228 adult patients with GC or GEC were
enrolled from Subang Jaya Medical Centre, Malaysia, for ret-
rospective (210) and prospective study. All patients were sub-
jected to the HER2 immunohistochemistry test using an FDA-
approved, standardized test kit. Carcinomas scoring 2+ on
immunohistochemistry were further tested with HER2 in situ
hybridization (ISH) using an FDA-approved test kit.
Results The overall rate of HER2 positivity in the population
studied was 24.6% (n = 56). The rate was significantly higher
in men than in women (29.6 vs. 16.3%; p = 0.024). HER2
overexpression was significantly more common in diffuse type
than in intestinal type of tumors (39.8 vs. 14.9%; p < 0.001). In
our study, out of 56 samples, 44 (78.6%) were considered for
gene amplification testing, out of which 40 (90.1%) samples
showed gene amplification. There was no statistically significant
correlation between HER2 positivity and patient age, race, tumor
location, tumor differentiation, and TNM staging.
Conclusions HER2 overexpression was evident in nearly
25% of the Malaysian patients with locally advanced or
metastatic gastric cancer. The overexpression correlated sig-
nificantly with male gender and diffuse-type tumors. The ma-
jority of the IHC-positive tumors demonstrated c-erb2 gene
amplification and this finding reached statistical significance.
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Introduction
The International Agency for Research on Cancer (IARC) sug-
gests that gastric cancer (GC) is the fifth most common cancer in
the world based on its GLOBOCAN 2012 project data. Gastric
cancer is also the third leading cause of cancer mortality in both
sexes worldwide (723,000 deaths) [1]. The majority of patients
with GC presents at an advanced stage and experiences signifi-
cant morbidity andmortality [2]. The age-standardized incidence
rate (ASR) of GC is about twice as high in men as in women [1].
More than 70% of GC cases are diagnosed in developing
countries. More than 727,000 cases of GC were diagnosed in
Asia in 2008 accounting for 11.9% of all the cancers diag-
nosed [3]. Nearly half the total global cases of GC occur in
Eastern Asia, mainly in China [1]. The report issued by the
National Cancer Registry, Malaysia, in 2006 showed that the
total incidence of stomach cancer in the country was 3.9% [4].
However, the incidence of GC varies among people of
Chinese, Malay, and Indian origin [5]. Higher rates of GC
have been observed in the Chinese population compared to
the Malay and Indian populations [6].
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Human epidermal growth factor receptor 2 (erb2/HER2) is a
member of the HER family and is a proto-oncogene encoded by
erb2 on chromosome 17. It plays a major role in promoting cell
proliferation and suppressing apoptosis and thus facilitates exces-
sive or uncontrolled cell growth and tumorigenesis. Although
HER2 expression was initially associated with breast cancer, it
has now been implicated in advanced gastric and gastroesopha-
geal junction cancer (GEC) [7]. While 15–25% of all patients
with breast cancer have been found to be HER2 positive, the rate
of HER2 positivity varies widely among patients with GC.
HER2 positivity has been found to range from 6.8–34% on
immunohistochemistry (IHC) and 7.1–42.6% on fluorescent in
situ hybridization (FISH) in GC [8].
HER2 is a well-established therapeutic target in breast cancer
[2]. Preclinical evidence attests to the significant antitumor effi-
cacy of anti-HER2 therapies (particularlymonoclonal antibodies)
in GC [9]. Trastuzumab, an anti-HER2 humanized monoclonal
antibody [10], already in use for prolonging overall survival and
progression-free survival in patients with HER2-positive breast
cancer, has now been shown to significantly prolong survival in
patients with GC and GEC. Other agents that target HER2, in-
cluding lapatinib, emtansine (T-DM1), and pertuzumab are also
being developed and have demonstrated promising results in
HER2-positive breast cancer [7]. The efficacy of lapatinib in
combination with capecitabine and oxaliplatin was investigated
in a randomized placebo-controlled phase III trial involving 545
patients with HER2-positive advanced gastroesophageal adeno-
carcinoma. The patients were randomly assigned to capecitabine
and oxaliplatin plus lapatinib 1250 mg or placebo daily. The
primary endpoint of the study was overall survival. There were
no significant differences between the two groups in terms of
overall survival although the lapatinib group demonstrated a sig-
nificantly higher response rate compared to the placebo group
[11]. The Trastuzumab for Gastric Cancer (ToGA) trial (a pro-
spective phase III open-label trial) screened 3803 patients with
GC/GEC for HER2 status with IHC and FISH test. Patients were
considered eligible for the study if their tumor samples were
scored as 3+ on IHC or if they were FISH positive
(HER2/centromericprobe forchromosome17[CEP17] ratio≥2).
In this study, 810 patientswere found to beHER2 positive. These
HER2-positive patients, when treated with trastuzumab in com-
bination with ongoing chemotherapy, showed significant im-
provement in overall survival as compared to patients who did
not receive trastuzumab (13.8 vs. 11. 1months; hazard ratio 0∙74;
95% CI 0∙60–0∙91; p = 0.0046). Post hoc analysis of two large
subgroups, one with high HER2 expression (IHC 2+ and FISH
positive or IHC 3+; n = 446) and the other with low HER2
expression (IHC 0 and FISH positive or IHC 1+ and FISH pos-
itive; n = 131) was performed. The analysis showed that patients
whose tumors had high HER2 expression had a high overall
median overall survival (16.0 months) with trastuzumab plus
chemotherapy compared to chemotherapy alone (11.8 months)
[12]. Thus, HER2 testing has emerged as a promising prognostic
marker that could benefit patients with GC/GEC if coupled with
an appropriate targeted therapy [2, 7, 10]. Studies conducted so far
suggest the need for optimizing HER2 testing as appropriate inter-
pretation of these test results could translate into delivery of opti-
mal therapy. It has been reported that only patients with high levels
of HER2 expression derive maximum benefit from trastuzumab
therapy [2]. The European Medicines Agency has now recom-
mended that Herceptin (trastuzumab) should be used only in pa-
tients with metastatic GC tumors that have HER2 overexpression
defined by IHC2+ and a confirmatory ISH+ result, or IHC3+
determined by an accurate and validated assay [13].
A highly varied epidemiological presentation of GC/GEC
warrants the conduct of well-designed studies in specific
populations/ethnic groups to establish the association between
HER2 overexpression and GC treatment. In a recently pub-
lished study in Japanese patients with GC, tissue expression of
HER2 was reported in 6.7% of the 105 patients screened [14].
According to the latest available cancer statistics inMalaysia
(2007), 630 cases of GC have been recorded in the country
[15]. However, no specific study data has correlated HER2
overexpression with the different stages of GC/GEC in the
Malaysian population. A study examining the frequency of
HER2 overexpression in GC/GEC in the Malaysian population
would therefore provide valuable data unique to Malaysian
patients and allow for cost-effective management of the cancer
from the standpoint of early diagnosis and optimal therapeutic
strategies. Hence, we conducted an observational study to ex-
amine the correlation of HER2 overexpression in GC/GEC
with parameters such as basic demography, race, pathological
subgroups, and site of origin in the Malaysian population.
Patients and Methods
Patients
A total of 228 patients with GC/GEC were enrolled from the
Subang Jaya Medical Centre, Malaysia, for retrospective
(n = 210) and prospective study (n = 18). The study included
men and women over 18 years of age residing in Malaysia,
diagnosed with locally advanced, metastatic or recurrent, his-
topathologically confirmed gastric or GEC. The reasons for
exclusion included (i) patients aged <18 years (ii) any other
stage of GC/GEC other than that given in the inclusion
criteria, and (iii) any other condition or criteria deemed inap-
propriate by the treating physician for enrollment in the study.
Study Design
This study was an investigator-initiated, observational study
(epidemiological study) wherein the data were collated in both
a retrospective and prospective manner.
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Objectives
The primary objective of the study was to determine the inci-
dence of HER2 positivity in patients with locally advanced or
metastatic GC and GEC inMalaysia. The secondary objective
was to evaluate correlation of HER2 overexpression with de-
mographic and clinicopathological parameters.
Study Methodology
The pathology records of all patients histopathologically di-
agnosed with GC/GEC at Subang Jaya Medical Centre
(SJMC) were obtained electronically from January 2013 to
December 2014 and investigations for HER2 status were in-
cluded in the study. Among these cases, 210 cases that satis-
fied the selection criteria were included for the retrospective
review. Selection of these retrospective cases was based on the
integrity and completeness of the data set. Additionally, 18
patients, who satisfied the criteria for enrollment, were includ-
ed in the study prospectively. For the prospective enrollment,
an open-label, non-randomized, non-interventional design
was followed. A cutoff date was set and all patients with
GC/GEC who consulted within this cutoff date were selected
for the prospective study. Patients who were already receiving
treatment for GC/GEC and those who required to be screened
for HER status were approached for consent. The approval of
the Ethics Committee of SJMC was taken for the study.
Laboratory Analysis
Tissue samples received from various participating centers
were subjected to histopathological examination to confirm
the diagnosis of GC and the cases were categorized according
to tumor grade and histological subtype.
Gene Amplification Testing
Patients with histologically confirmed gastric adenocarcinoma
were subjected to HER2 IHC test using an FDA-approved,
standardized test kit (Hercep test kit (DakoCytomation
Denmark A/S, Glostrup, Denmark). Generally, tumors which
were unequivocally confirmed as positive (3+) or negative (0)
on IHCwere not tested further. However, 30 cases which were
3+ on IHC and all tumors with equivocal results as 2+ on IHC
were also tested by dual in situ hybridization (DISH) method
to confirm or refute the presence of gene amplification and to
explore the presence of ploidy. Dual in situ hybridization was
performed using the PathVysion HER2 DNA probe kit (Vysis
Inc., Downers Grove, IL) according to the recommendation
by the European Medicines Agency (EMA), utilizing the
Ventana Ultra platform.
Study Endpoints
The frequency of HER2 positivity in patients with GC/GEC in
Malaysia within the sample size chosen was determined as the
primary outcome measure. The secondary outcome measures
for the study were as follows:
& Correlation/association of HER2 overexpression with de-
mographic parameters (age, sex, race)
& Correlation/association between HER2 overexpression
status and clinicopathological parameters such as (a) tu-
mor location (GC or GEC); (b) tumor subtype (Lauren
classification: intestinal, diffuse, or mixed); (c) tumor dif-
ferentiation (well, moderately, or poorly differentiated);
(d) pathological TNM staging (pTNM); and (e) c-erb2
gene amplification.
Statistical Analysis
Data analysis was done using SPSS Software version 20.
Demographic characteristics were summarized using descrip-
tive statistics (mean and standard deviation (SD) for continu-
ous variables, and frequency and percentages for categorical
variables). Chi-squared test (with Yate’s correction wherever
necessary) was used to test the statistical significance of the
association of various categorical variables with HER2 status.
Continuous variables were grouped for this analysis. A p val-
ue of <0.05 was considered statistically significant. Higher
p values indicate higher confidence in rejecting the null hy-
pothesis for no association.
Results
Patient Demographics and Tumor Characteristics
The median age of patients was 62 years (range 26–89 years)
with the majority being of Chinese (74.1%) followed by
Indian origin (7%) (Table 1). Of the 228 cases enrolled in
the study, 24.6% (n = 56) tested positive for HER2. The loca-
tion of the tumor was the gastric body in 76.7% of patients.
Histological sub typing revealed that 45.2% of the tumors
were of the Lauren intestinal type followed by the diffuse
type (41.2%); 12.7% of the tumors were classified as
Bindeterminate^ when subtyping was not possible. Poorly dif-
ferentiated tumors were observed in 125 cases (54.8%) and
42.5% of patients had moderately differentiated tumors. Stage
III and IV tumors were observed in 60.1 and 18.9% cases,
respectively. Gene (c-erb2) amplification was observed in
20.6% of the study population (Table 1).
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Association of HER2 Status with Demographic
and Patients Characteristics
A statistically significant correlation was observed between
HER2 positivity and male gender. The rate of HER2 positivity
was significantly higher in men (29.6%) than women (16.3%)
(p = 0.024). Notably, 46.7% of the Malay population was
tested positive for HER2 compared to 23.7% in the Chinese
population although the maximum number of HER2-positive
patients was of Chinese origin. The maximum number of
HER2-positive tumors was detected in patients aged more
than 30 years (Table 2).
Association/Correlation of HER2 Status
with Clinicopathological Features
There was no statistically significant correlation between HER2
positivity and age, race, tumor location, tumor differentiation,
and TNM staging. A statistically significant correlation was ob-
served between HER2 positivity and diffuse-type tumor and c-
erb2 gene amplification.
Tumor Location
Tumors located in different parts of the stomach such as the
fundus, lesser curvature, body, antrum, and pyloruswere grouped
as gastric body tumors, whereas tumors located in the cardia,
esophagus, gastroesophageal junction (GEJ), proximal stomach,
and cardio esophageal junction were grouped as GEC tumors.
The incidence of HER2 positivity in GEC (34%) was more than
that in gastric body (21.7%); however, this association was not
statistically significant (p = 0.070) (Table 2).
Histological Grade: Tumor Differentiation
HER2 positivity was not statistically associated (p = 0.063)
with the histological grade of the tumor; 50% of well differ-
entiated and 30% of moderately differentiated tumors tested
positive for HER2 compared with 19% of poorly differentiat-
ed tumors (Table 2).
Tumor Subtype: Lauren Classification
HER2 overexpression was significantly more common
(p < 0.001) in diffuse-type tumors (39.8%) than intestinal type
tumors (14.9%) (Table 2 and Fig. 1).
Tumor Staging
Overall, 32.6% of stage IV cases tested positive for HER2 as
compared to 24.2% of stage III cases (p = 0.284) (Table 2).
Gene (c-erb2) Amplification
Only tumors with IHC 2+ (n = 16) and 3+ score (n = 40) were
considered for DISH. Of the 16 cases with IHC 2+ score, DISH
was not performed for two tumors as insufficient tumor tissue
was available for analysis. Of the remaining 14 tumors, 11
(78.6%) showed gene amplification and 3 tumors did not show
gene amplification. Of the 40 cases with IHC 3+ score, DISH
was not performed for 10 tumors due to insufficient lesional
tissue available for analysis in 6 cases and failure to detect hy-
bridization signals in 4 cases (due to pre-analytical factors). Of
the remaining 30 cases, 29 cases (96.7%) showed gene amplifi-
cation and 1 tumor did not show erb2 gene amplification; this is
likely to be a result of tumor heterogeneity for c-erb2 expression,
Table 1 Patient demographic and tumor characteristics (n = 228)
Variable Value, n (%)
Gender























Well differentiated 6 (2.6)
Moderately differentiated 97 (42.5)









which is a well-recognized phenomenon in gastric cancer. The
HER2 positivity on IHCwas significantly associated (p < 0.001)
with gene amplification (Table 3).
Discussion
The human epidermal growth factor receptors play a central
role in the pathogenesis of several human cancers due to their
function in regulating cell growth, survival, and differentiation
via multiple signal transduction pathways. HER2, which is
expressed in many tissues, plays a major role in facilitating
uncontrolled cell growth and differentiation. Most studies on
HER2 have been carried out in patients with breast cancer.
However, thanks to the increasing awareness of the clinical
significance of HER2 biology, the role of HER2 in other can-
cers such as stomach, ovary, uterine serous endometrial carci-
noma, colon, bladder, lung, uterine cervix, head and neck, and
esophagus cancer has also been identified [16]. This has re-
sulted in rigorous testing of gastric and GEC, notably with a
view to improve survival outcomes.
HER2 overexpression in GC using immunohistochemistry
(IHC) was first described in 1986 [9]. More than 20% of gastric
Table 2 Tumor characteristics by
HER2 positivity Tumor characteristics HER2-negative n (%) HER2-positive n (%) p value
Gender 0.024*
Male 100 (70.4) 42 (29.6)
Female 72 (83.7) 14 (16.3)
Age group (years) 0.382
<30 5 (100) 0 (0)
31–45 22 (71.0) 9 (29.0)
46–60 53 (81.5) 12 (18.5)
>60 92 (72.4) 35 (27.6)
Ethnicity 0.596
Chinese 129 (76.3) 40 (23.7)
Indian 12 (75) 4 (25)
Malay 8 (53.3) 7 (46.7)
Others 23 (82.1) 5 (17.9)
Tumor location 0.070
Gastric body 137 (78.3) 38 (21.7)
GEC 35 (66.0) 18 (34.0)
Tumor subtype <0.001*
Intestinal 80 (85.1) 14 (14.9)
Diffuse 62 (60.2) 41 (39.8)
Indeterminate 29 (100) 0 (0)
Tumor differentiation 0.063
Well differentiated 3 (50.0) 3 (50.0)
Moderately differentiated 68 (70.1) 29 (29.9)
Poorly differentiated 101 (80.8) 24 (19.2)
TNM staging 0.284
II 5 (83.3) 1 (16.7)
III 108 (75.8) 29 (24.2)
IV 29 (67.4) 14 (32.6)
NK 30 (71.4) 12 (28.6)
*p < 0.05
Fig. 1 Association of HER2 status with different tumor subtypes
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cancers have demonstrated HER2 overexpression and/or ampli-
fication with the percentage increasing to 33% in GEC tumors
[10]. In our study, HER2 positivity was evident in 24.6% of
patients. Similar HER2 overexpression rates were reported in a
Japanese study, where the rate of HER2 overexpression in 200
resected tumors was found to be 23%. In the same study, gene
amplification by FISH was identified in 27.1% of the cases [17].
In our study, out of 56 samples, 44 (78.6%) were considered for
gene amplification testing, out of which 40 (90.1%) samples
showed gene amplification. Tumors with IHC3+ score showed
96.7% correlation with c-ERB-2 gene amplification, and 78.6%
tumors with IHC2+ score showed c-ERB-2 gene amplification.
In our study, no statistically significant correlation was ob-
served between HER2 positivity and age, race, tumor location,
tumor differentiation, and TNM staging. However, a statistically
significant correlation was observed between HER2 positivity
and male gender (29.6%; p = 0.024), which may be attributable
to the higher number of male patients in our study. Furthermore,
gastric adenocarcinomas are more common in males [18].
Although statistically non-significant, HER2 expression was
more common in Malay patients (46.7%) followed by patients
of Indian origin (25%). Furthermore, studies have reported that
HER2 expression is more frequent in GEC compared to GC [9].
In our study, the incidence of HER2 positivity was found to be
greater in GEC than in gastric body cancers, but this finding did
not reach statistical significance. This association has been con-
firmed by the ToGA study with a large number of patients which
demonstrated HER2 positivity in 32 and 18% in GEC and GC,
respectively. Several recent studies have demonstrated an associ-
ation between HER2 expression and tumors with intestinal type
histology. The contributing factors for HER2 overexpression in
intestinal type GC are quite complex and require extensive in-
vestigation. The association between this oncogene and a specific
histologic type indicates that certain characteristics may be pref-
erentially expressed together. However, since not all intestinal
type tumors are associated with HER2 expression, more than
one factor may be involved [9]. However, in our study, HER2
expression was significantly more common in diffuse-type tu-
mors (p < 0.001) than in intestinal type tumors.
Our study showed a non-significant association between
HER2 expression and well differentiated tumors. Studies have
shown both an association and nonassociation between HER2
overexpression and tumor differentiation. This discrepancy may
be attributed to varying sample sizes and lower prevalence of
HER2 in GC and GEC. Varying methods of evaluation and
scoring schemes with different cutoff points before the establish-
ment of standard guidelines may also have contributed [19].
However, no significant association was observed between
HER2 expression and TNM staging.
Increasing evidence suggests that HER2 is an important bio-
marker of GC and GEC. Many studies have evaluated the asso-
ciation of HER2 status and prognosis in patients with GC. The
findings have been inconsistent with some studies demonstrating
a significantly worse prognosis in patients with HER2 positivity
[20, 21] whereas others showing no association between the
HER2 status and prognosis [22, 23]. A few studies have demon-
strated a longer median overall survival in HER2-positive com-
pared to HER2-negative patients [22, 24]. In a study by
Nakajima et al., HER2 overexpression along with nodal metas-
tasis was considered as one of the independent prognostic factors
[25]. Hence, the relationship betweenHER2 status and prognosis
in GC remains a subject mired in controversy [7].
In addition to being implicated in the pathogenesis of can-
cers, HER2 has also been evaluated as a therapeutic target. It
has been successfully targeted in both breast cancers and GC/
GEC [16]. Trastuzumab was the first HER2-targeted agent
which demonstrated significant clinical activity in the ad-
vanced GC and GEC settings [26]. In the ToGA trial, addition
of trastuzumab to chemotherapy increased the overall survival
from 11.1 to 13.8 months (HR = 0.74, 95% CI = 0.60–0.91;
p = 0.0046). There was also a significant improvement in
progression-free survival and response rate with trastuzumab
[12]. Unlike trastuzumab, no benefit in terms of overall sur-
vival (OS) was evident when bevacizumab was added to a
combination of cisplatin and fluoropyrimidine in patients with
GC/GEC [27]. Likewise, cetuximab therapy in combination
with capecitabine and cisplatin did not achieve the primary
endpoint with a median progression-free survival (PFS) of
4.4 months compared to 5.6 months in patients who received
capecitabine-cisplatin alone [28]. The REAL-3 study which
involved treatment with modified epirubicin/oxaliplatin/cape-
citabine (EOC) and panitumumab was terminated prematurely
because the patients with advanced esophagogastric adenocar-
cinoma had a statistically significant lower OS [29]. The com-
bination of fluoropyrimidine and platinum-containing chemo-
therapy, with the addition of trastuzumab remains the standard
of care in HER2 positive populations [26]. The introduction of
trastuzumab has opened up avenues for the development of
Table 3 c-erb2 gene
amplification No. of samples tested on DISH which are positive on IHC (2+ and 3+) (n = 56) 44 (78.6)
Not tested 12 (21.4)




anti-HER2 drugs that may be useful in the treatment of HER2-
positive gastric cancer [7].
The Malaysian Cancer Statistics 2007 reported a total of
630 GC cases nationwide. A sample size of 228 in our study
would therefore represent approximately one third of the pop-
ulation. Hence, the sample size used in our study can be con-
sidered an acceptable representation of the Malaysian popula-
tion with GC/GEC.
Conclusion
Accurate assessment of HER2 overexpression in GC/GEC in
the Malaysian population provides valuable data unique to
Malaysian patients, and allows for cost-effective management
of the cancer in this population. Nearly 25% of the population
demonstrated HER2 overexpression, which significantly cor-
related with male gender and diffuse-type GC. The rate of
HER2 positivity was higher in the Malays than in other races.
The sample size was an acceptable representation of the
Malaysian population with GC/GEC. However, a larger pro-
spective study will be better posed to endorse or refute the
findings of this study. Furthermore, majority of the IHC-
positive tumors demonstrated c-erb2 gene amplification and
this association was statistically significant.
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